TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04270864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 20mg (4mL) IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 20mg (4mL) IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 360mg IV then 480mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 360mg IV then 480mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilsotolimod
Description: 8 mg (2mL) IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilsotolimod
Description: 8 mg (2mL) IT
Study: NCT05367817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise therapy
Description: Participants perform specific neuromuscular exercises aimed at enhancing the sensorimotor control of the wrist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training program
Description: Participants perform range of motion exercises for the wrist.
Study: NCT04430231

Intervention type: OTHER
Intervention: Wait list time

Intervention type: OTHER
Intervention: Wait list time

Intervention type: OTHER
Intervention: Wait list time

Intervention type: OTHER
Intervention: Wait list time
Study: NCT04086212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icodextrin, xylitol and carnitine solution for peritoneal dialysis
Description: Patients will receive a long dwell exchange for three days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EXTRANEAL 7.5G/100Ml Peritoneal Dialysis Solution
Description: Patients will receive a long dwell exchange for three days.
Study: NCT02141815

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arabinoxylan-oligosaccharides

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrine
Study: NCT04613661

Intervention type: OTHER
Intervention: Australian Spasticity Assessment Scale
Description: Australian Spasticity Assessment Scale is a clinical measure to assess the severity of spasticity

Intervention type: OTHER
Intervention: Australian Spasticity Assessment Scale
Description: Australian Spasticity Assessment Scale is a clinical measure to assess the severity of spasticity
Study: NCT01154088

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mencevax ACWY
Description: One dose, Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' meningococcal serogroup A, C, W-135, Y tetanus toxoid conjugate investigational vaccine [GSK 134612]
Description: One dose, Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' meningococcal serogroup A, C, W-135, Y tetanus toxoid conjugate investigational vaccine [GSK 134612]
Description: One dose, Intramuscular injection
Study: NCT04150484

Intervention type: OTHER
Group type: OTHER
Intervention: Mediterranean diet, physical exercise and mindfulness workshops
Description: a group of dietary intervention, physical exercise and mindfulness and another control group, and a longitudinal follow-up was carried out for 6 months from the beginning of the intervention.
Study: NCT04430842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBS10072S
Description: QBS10072S targets cancers with high LAT1 expression.
Study: NCT02179606

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermalax Implant Plus
Description: Dermalax implant plus injection into one nasolabial fold(NFL) of one side of the face(blinded, split-face study design) in the initial treatment period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermalax Implant Plus
Description: Dermalax implant plus injection into one nasolabial fold(NFL) of one side of the face(blinded, split-face study design) in the initial treatment period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Sub-Q
Description: Restylane Sub-Q injection into one nasolabial fold(NFL) of one side of the face(blinded, split-face study design) in the initial treatment period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane Sub-Q
Description: Restylane Sub-Q injection into one nasolabial fold(NFL) of one side of the face(blinded, split-face study design) in the initial treatment period.
Study: NCT03490461

Intervention type: DRUG
Intervention: Statin
Description: Patients who used statins over 1 month for the treatment of dyslipidemia after LT were enrolled as statin group.
Study: NCT00752258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mentor Purified Toxin Botulinum Toxin Type A
Description: All subjects will receive five 0.1 mL intramuscular injections (two in each corrugator and one in the procerus muscle) at each Treatment Visit. The total treatment dose (sum of the five injections) to be administered will be 30 U of Mentor Purified Toxin. Subjects will have many Treatment Visits throughout the course of the three-year study.
Study: NCT01687569

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Cracker Snack
Description: Base cracker snack
Study: NCT04292925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New treatment protocol
Description: The new treatment protocol focuses on training of executive processes using remedial strategies and on promoting the use of meta-cognitive strategies. Goal directed activities are used to improve the underlying cognitive process and transfer of the learned skill to everyday function will be encouraged.
Study: NCT01687569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Cracker Snack 1
Description: Cracker snack containing test ingredient 1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Cracker Snack 2
Description: Cracker snack containing test ingredient 2
Study: NCT04292925

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: conventional therapy
Study: NCT03360006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-744
Description: Tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-744
Description: Tablet, oral
Study: NCT04694950

Intervention type: PROCEDURE
Intervention: Usual care
Description: Intravenous morphine according to clinician´s discretion.
Study: NCT02012465

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin protocol
Description: Within 24 hours of admission for diabetic participants, the inpatient oncology team will consult the endocrine team to apply the following part of the protocol, confirm NPH insulin dosing, and ensure that oral hypoglycemics are held.~The following basal-bolus protocol is standard of care for inpatient diabetics requiring insulin at Barnes Jewish Hospital. The alternative practice has been to use 60-80% of the home insulin regimen while patients are hospitalized. For patients using home insulin, the admitting oncology team will enact one of these methods while awaiting the endocrine service's formal recommendations.~* Determine basal-bolus insulin requirement for the patient based on body weight: Patient weight (kg) x 0.5-0.7 Units/kg = Units of total insulin per 24 hours~* The TDD can be divided into 50% basal (glargine) and 50% meal time (lispro) insulin, plus sliding scale insulin (lispro).
Study: NCT04766957

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Idracare
Description: Treatment will last 3 months (12 weeks). The treatment will be applied 2 times a week, preferably at night before going to bed.
Study: NCT03535454

Intervention type: OTHER
Intervention: working hours
Description: weekly working hours

Intervention type: OTHER
Intervention: working hours
Description: weekly working hours

Intervention type: OTHER
Intervention: working hours
Description: weekly working hours

Intervention type: OTHER
Intervention: working hours
Description: weekly working hours
Study: NCT01470781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BrainWorks
Description: 13 programs targeting cognition in 4 separate domains: Auditory processing, visual processing, social cognition, and executive functioning. Games are imbedded in a format that is engaging and interactive. Animated characters serve as directors for each program, explaining the tasks in both verbal and written formats and providing feedback on each trial and overall after each activity. Users move systematically through the programs and can track their progress as the go. Each session includes activities from several different games to maintain interest and train a variety of skills; however, games are presented in the order of domains listed above (i.e. auditory, then visual, then social, and finally executive) to avoid stimulus interference during the training.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Computer Control
Description: Sessions will involve generic computer games administered via the game interface Sporcle. Sporcle is a game site that offers a collection of quiz-type activities available on line. The activities include typing, basic timed arithmetic (e.g. simple addition); picture identification (e.g. name the corporate logo; name the sitcom), and subject-based quizzes in areas like history (e.g. name the US presidents), geography (e.g. name the state capitals), and literature (e.g. book title fill-in-the-blank). An administrator can track the activity of subjects including when they logged in, which games they played and for how long, and what their accuracy was on each game. We will use a pre-developed game schedule that includes a mix of each type of game in each session, and ensures that subjects are playing the same games in the same order. This format was developed to mirror the treatment condition, as subjects are given a variety of specific games to play at each session.
Study: NCT02657018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MOBIGAME
Description: Mobile phone based game-like software application and platform (MOBIGAME) that includes individualized and structured exercise regimens (endurance, strength, balance and flexibility) that are based on the user's individual fitness evaluation (through established fitness tests) and incorporated into the story line of a gardening simulation game.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: One-time standard lifestyle counseling including the promotion of baseline activities of daily life as well as a structured exercise plan including strength and endurance exercises with moderately increasing intensity and duration that is to be implemented autonomously.
Study: NCT01618227

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Joint Active Systems (JAS) Static progressive splint
Description: Subjects will have a standard rehabilitation program including physical or occupational therapy and home exercises throughout the study. Upon receipt of the splint, subjects will be instructed in proper application and use by their treating therapist or a representative of the company. Subjects will be instructed to follow the daily splint wearing protocol provided by the device manufacturer.
Study: NCT04326296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-L1 Monoclonal Antibody Combined With Lenalidomide
Description: PD-L1 monoclonal antibody was administered by intravenous drip every 3 weeks.Lenalidomide was administered orally, 25mg once a day on days 1-21 of each repeat cycle of 28 days.
Study: NCT01618227

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rehabilitation without splinting
Description: Subjects will have a standard rehabilitation program including physical or occupational therapy and home exercises without additional splinting.
Study: NCT03955952

Intervention type: PROCEDURE
Intervention: Bariatric Surgery
Description: Patients chosen using the following codes:~Current Procedural Terminology (CPT): 43633, 43634, 43770, 43775, 43644, 43645, 43659, 43842, 43843, 43844, 43845, 43846, 43847 International Classification of Diseases (ICD): 44.31, 43.82,44.95, 43.89, 44.38, 44.39, 44.68 Healthcare Common Procedure Coding System (HCPCS): S2082, S2085
Study: NCT00263783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-522
Description: MEDI-522 will be administered at doses of 1.0, 2.0, 4.0, 6.0, 8.0, and 10.0 mg/kg. \[As a 30 minute IV infusion initially as a single dose (single-dose treatment period) and 2 to 5 weeks later as weekly doses (multiple-dose treatment period) for up to 1 year.\]
Study: NCT03814278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: complete bed rest
Description: Patients in this group received standard care for PPROM according to the institution protocol, including antepartum confinement to bed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: activity restriction
Description: Patients in this group received standard care for PPROM according to the institution protocol but to had bathroom privileges and walks to the ward canteen four times per day.
Study: NCT02544841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safer Sex Intervention (SSI)
Description: Safer Sex Intervention (SSI) is an in-person, individual-level, clinic-based intervention implemented by a female health educator trained in the intervention. It is intended to be implemented in one initial session lasting 30-50 minutes and three booster sessions lasting 10-30 minutes at one, three, and six month intervals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Female Sexual Health
Description: Female Sexual Health is a knowledge-based intervention that intends to provide information on how STIs are contracted, the consequences of contracting STIs, and how to prevent them. Female Sexual Health includes the information-only component of the first session of SSI and baseline exposure to a health educator but does not include booster sessions.
Study: NCT02767596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide
Study: NCT01553240

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS and functional MRI (Magstim)
Description: single and paired pulse low frequency TMS. 3T structural MRI scans, amplitude modulated continuous arterial spin labeling( CASL) perfusion imaging sequence optimized for 3T is employed for perfusion MR scans using GE FAIR sequence for parallel imaging.
Study: NCT03364764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: On refractory PRCA patients, sirolimus was tried. Dosage: 2mg QD for the first day, then 1 mg QD. Medication time should last at least 6 months.
Study: NCT02557204

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional technique
Description: the nasogastric tube will be inserted gently through a selected nostril with the head being maintained in the neutral position.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: head in the lateral position technique
Description: the patient's head will be turned to the right lateral position. Nasogastric tube will be inserted through the right nostril without any maneuvers of the neck.
Study: NCT02767596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basal insulins
Description: patients are on basal insulin treatment
Study: NCT02557204

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endotracheal tube assisted technique
Description: Nasogastric tube will be inserted the trimmed 7.5 mm internal diameter endotracheal tube what cut proximal end with sterile scissors and endotracheal tube will be advanced blindly into the oral cavity to a depth of approximately 18 cm without laryngoscope together the nasogastric tube.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: videolaryngoscope technique
Description: Nasogastric tube was inserted transnasally and advanced into esophagus under direct vision.
Study: NCT01231503

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG
Description: 1 dose, intradermal route, in shoulder at birth (=\< 7 days of age)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: 1 dose, intradermal route, in shoulder at birth (=\< 7 days of age)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: 1 dose, intradermal route, in shoulder at birth (=\< 7 days of age)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: 1 dose, intradermal route, in shoulder at birth (=\< 7 days of age)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: 1 dose, intradermal route, in shoulder at birth (=\< 7 days of age)
Study: NCT01759849

Intervention type: OTHER
Intervention: Allergen
Description: Allergen extract is administered by inhalation.
Study: NCT00908791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conjugated Linoleic Acid (CLA)
Description: Conjugated linoleic acid (CLA, Clarinol™) oral soft gel capsules will be administered in an open-labeled, manner to all subjects enrolled in the study. Subjects will be treated with 7.5 grams of oral CLA daily, taken in divided dose, twice daily between 8 am and 12 noon and between 8 pm and 12 midnight. CLA will be taken for a minimum of ten days prior to surgical resection of their breast malignancy. In the event that the subject's surgical resection date is delayed, subjects may take CLA for up to 28 days. The last dose of CLA prior to the surgical resection will be taken at 12 midnight or as close as possible to that time and the patient will record the time of the last dosing.
Study: NCT00425061

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA-638
Description: SC Injection, 12 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA-638
Description: SC Injection, 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01679067

Intervention type: PROCEDURE
Intervention: colonoscopy with endoscopic biopsies
Study: NCT03663465

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hawthorn
Description: Hawthorn tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hawthorn
Description: Hawthorn tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGAs
Description: SGAs tablet
Study: NCT03743103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brevibloc, 10 Mg/mL Intravenous Solution
Description: 10 mL/h every 5 minutes until reaching the pressure target

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroprusside, Sodium
Description: 0.5 ug/kg/min every 3 minutes until reaching the pressure target

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroprusside, Sodium
Description: 0.5 ug/kg/min every 3 minutes until reaching the pressure target
Study: NCT00970632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg
Description: Tadalafil 5 mg po QD for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet po QD for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Tamsulosin 0.4 mg po QD for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo capsule po QD for 12 weeks
Study: NCT00687349

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training Program Intervention
Description: Resident or NP Student receives the educational intervention during 8 half-day sessions.
Study: NCT03438461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant 40 mg
Description: Seltorexant 40 mg as two tablets of 20 mg will be administered as Formulation 1, 2 and 3 orally in Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant 20 mg
Description: Seltorexant as a tablet of 20 mg will be administered as Formulation 1, 2 and 3 orally in Part 2.
Study: NCT00771251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 148
Description: 50 mg or 100 mg given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 116.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 148
Description: 50 mg or 100 mg given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 116.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo identical in appearance to CNTO 148 given as a subcutaneous (under the skin) injection once every 4 weeks until week 12 and then CNTO148 50mg SC injections every 4 weeks from week 16 until week 116.
Study: NCT00166257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous closure of patent foramen ovale
Description: Percutaneous implantation of an AMPLATZER® PFO Occluder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical antitrhombotic treatment
Description: Investigator's choice: Anticoagulation to INR 2.0 - 3.0 OR Aspirin 100-325 mg/d OR Clopidogrel 75-150 mg/d
Study: NCT03969303

Intervention type: DEVICE
Intervention: Notal Vision Optical Coherence Tomography Device Version 2.5 (NOTAL-OCT V2.5)
Description: OCT SCAN
Study: NCT00902343

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nomogram-based selection for acute normovolemic hemodilution
Description: Will use the nomogram to determine whether or not the patient needs ANH during surgery. The nomogram assigns a point value to certain pre-op factors to determine whether or not the patient will need an ANH. Preoperative factors that will be used are platelet count, planned amount of liver to be removed, hemoglobin level, if the surgeon needs to operate on any organ outside of the liver to remove the tumor, and the patients health overall.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard selection for ANH based on a planned resection of 3 or more segments
Description: Will use the planned amount of liver to be removed to determine whether or not the patient needs an ANH during surgery.
Study: NCT02070627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green (ICG)
Description: 60-30 minutes prior to cholecystectomy, 2.5 mg of indocyanine green (ICG) will be injected intravenously. An additional 2.5 mg of ICG may be injected intraoperatively if the fluorescence fades prior to imaging.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near Infrared Fluorescence Cholangiography (NIRF-C)
Description: Near infrared fluorescence cholangiography will be performed intraoperatively in order to image anatomy.
Study: NCT01932736

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: changing ear canal pressure
Description: ear canal pressure changes: pressure varied from +/-40 decapascals
Study: NCT03410472

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web based diet application
Description: This group will be asked to record their diets for 8 weeks after being told an approximate calorie goal. This group will receive weekly emails with tips on how to eat healthy